NANEXA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.606 SEK | -5.31% |
|
-8.46% | -50.73% |
| Apr. 16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
| Mar. 08 | Transcript : Nanexa AB - Special Call |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 158.4 | 251.5 | 202.8 | 140.4 | 74.66 | 82.23 | - |
| Enterprise Value (EV) 1 | 158.4 | 242.7 | 97.12 | 221.6 | 9.488 | 16.73 | 0.2315 |
| P/E ratio | -11.9 x | - | -3.96 x | -2.39 x | -1.13 x | 15.2 x | 2.75 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 18.1 x | - | 11.2 x | 4.98 x | 1.26 x | 1.15 x | 1.18 x |
| EV / Revenue | 18.1 x | - | 5.35 x | 7.87 x | 0.16 x | 0.23 x | 0 x |
| EV / EBITDA | - | - | -3.43 x | -4.67 x | -0.57 x | 4.18 x | 0.01 x |
| EV / FCF | - | - | -2.95 x | -5.12 x | -0.12 x | 3.72 x | -0.02 x |
| FCF Yield | - | - | -33.9% | -19.5% | -811% | 26.9% | -5,398% |
| Price to Book | - | - | 0.94 x | 1.29 x | 1.74 x | 0.55 x | 0.46 x |
| Nbr of stocks (in thousands) | 15,160 | 21,224 | 50,696 | 50,696 | 60,696 | 135,696 | - |
| Reference price 2 | 10.45 | 11.85 | 4.000 | 2.770 | 1.230 | 0.6060 | 0.6060 |
| Announcement Date | 2/28/20 | 5/3/21 | 2/17/22 | 2/16/23 | 2/21/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 8.73 | 18.16 | 28.18 | 59.49 | 71.3 | 69.5 |
| EBITDA 1 | - | -28.35 | -47.48 | -16.76 | 4 | 29 |
| EBIT 1 | - | -35.82 | -57.98 | -76.62 | 16 | -4.8 |
| Operating Margin | - | -197.25% | -205.79% | -128.81% | 22.44% | -6.91% |
| Earnings before Tax (EBT) 1 | - | -36.01 | -58.64 | -76.51 | 16 | -4.3 |
| Net income 1 | - | -36 | -58.57 | -76.4 | 16 | -4.3 |
| Net margin | - | -198.23% | -207.88% | -128.43% | 22.44% | -6.19% |
| EPS 2 | -0.8800 | -1.010 | -1.160 | -1.090 | 0.0400 | 0.2200 |
| Free Cash Flow 1 | - | -32.89 | -43.29 | -76.91 | 4.5 | -12.5 |
| FCF margin | - | -181.12% | -153.66% | -129.29% | 6.31% | -17.99% |
| FCF Conversion (EBITDA) | - | - | - | - | 112.5% | - |
| FCF Conversion (Net income) | - | - | - | - | 28.12% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/17/22 | 2/16/23 | 2/21/24 | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 81.2 | - | - | - |
| Net Cash position 1 | - | 8.81 | 106 | - | 65.2 | 65.5 | 82 |
| Leverage (Debt/EBITDA) | - | - | - | -1.71 x | - | - | - |
| Free Cash Flow 1 | - | - | -32.9 | -43.3 | -76.9 | 4.5 | -12.5 |
| ROE (net income / shareholders' equity) | - | - | -37% | -45% | -74.6% | 3.8% | 18.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 4.250 | 2.150 | 0.7100 | 1.100 | 1.330 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | - | 7.76 | 7.77 | 34.2 | 2 | 2 |
| Capex / Sales | - | - | 42.75% | 27.57% | 57.57% | 2.81% | 2.88% |
| Announcement Date | 2/28/20 | 5/3/21 | 2/17/22 | 2/16/23 | 2/21/24 | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -50.73% | 7.5M | |
| -10.84% | 187M | |
| -59.36% | 82M |
- Stock Market
- Equities
- NANEXA Stock
- Financials Nanexa AB
